Impact of preexisting circulating effector T cells on the outcome of ABO-incompatible adult LDLT

Dig Dis Sci. 2009 Oct;54(10):2253-63. doi: 10.1007/s10620-008-0618-y. Epub 2008 Dec 11.

Abstract

Our aim was to clarify the significance of phenotype of circulating CD8 T(+) cells on the outcome of ABO-incompatible (ABO-I) living donor liver transplantation (LDLT). Twenty-six recipients undergoing ABO-I LDLT and 92 undergoing ABO-compatible (ABO-C) LDLT were classified into three groups according to preoperative proportion of CD8 T(+) cells: naive-dominant (group I), effector memory-dominant (group II), and effector-dominant (group III) recipients. The clinical courses were analyzed. The results showed that in ABO-C groups I and II and in ABO-I group I, effector cells remained above the pretransplant levels after tacrolimus administration. However, in ABO-C group III and ABO-I groups II and III, effector cells were down-regulated for a prolonged period, along with markedly decreased perforin expression and frequent life-threatening complications. ABO-I group II and group III recipients had higher infection rates. It was concluded that recipients with preexisting high effector CD8 T(+) cells are unfavorable candidates for ABO-I LDLT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ABO Blood-Group System / immunology*
  • Adult
  • Aged
  • Blood Group Incompatibility / immunology*
  • CD8-Positive T-Lymphocytes / immunology*
  • Female
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Liver Transplantation / immunology*
  • Living Donors*
  • Male
  • Methylprednisolone / pharmacology
  • Middle Aged
  • Phenotype
  • Tacrolimus / pharmacology

Substances

  • ABO Blood-Group System
  • Immunosuppressive Agents
  • Tacrolimus
  • Methylprednisolone